Cao O, Loduca P A, Herzog R W
Department of Pediatrics, University of Florida, Gainesville, FL 32610, USA.
J Thromb Haemost. 2009 Jul;7 Suppl 1(Suppl 1):88-91. doi: 10.1111/j.1538-7836.2009.03417.x.
The immune response to coagulation factors VIII or IX, in particular formation of inhibitory antibodies, complicates treatment of hemophilia. Therefore, a number of recent studies in animal models have explored novel approaches toward induction of immune tolerance in protein or gene replacement therapy. Strong evidence has emerged that regulatory T cells (Treg) are an important component of the mechanism by which tolerance is maintained and inhibitor formation, a T help dependent response, is prevented. Limited data in patients also support this concept. In particular, CD4+ CD25+ FoxP3+ Treg, whether naturally occurring or induced, have been invoked in suppression of antibody and of cytotoxic T lymphocyte responses to the therapeutic clotting factor. This review summarizes the data on this emerging concept of Treg-mediated regulation of the immune response in treatment of hemophilia, strategies and mechanisms of Treg induction and function, and the implications for development of immune tolerance protocols.
针对凝血因子VIII或IX的免疫反应,尤其是抑制性抗体的形成,使血友病的治疗变得复杂。因此,最近在动物模型中的一些研究探索了在蛋白质或基因替代疗法中诱导免疫耐受的新方法。有力的证据表明,调节性T细胞(Treg)是维持耐受和防止抑制剂形成(一种T辅助依赖性反应)机制的重要组成部分。患者中的有限数据也支持这一概念。特别是,CD4 + CD25 + FoxP3 + Treg,无论是天然存在的还是诱导产生的,都被认为可抑制对治疗性凝血因子的抗体和细胞毒性T淋巴细胞反应。本综述总结了关于Treg介导的血友病治疗免疫反应调节这一新兴概念的数据、Treg诱导和功能的策略及机制,以及对免疫耐受方案开发的影响。